Your browser doesn't support javascript.
loading
Late-occurring and Long-circulating Metabolites of GABAAα2,3 Receptor Modulator AZD7325 Involving Metabolic Cyclization and Aromatization: Relevance to MIST Analysis and Application for Patient Compliance.
Gu, Chungang; Artelsmair, Markus; Elmore, Charles S; Lewis, Richard J; Davis, Patty; Hall, James E; Dembofsky, Bruce T; Christoph, Greg; Smith, Mark A; Chapdelaine, Marc; Sunzel, Maria.
Affiliation
  • Gu C; DMPK, IMED Oncology, AstraZeneca, Waltham, Massachusetts (C.G); Early Chemical Development, IMED Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (M.A., C.S.E); Medicinal Chemistry, IMED Respiratory Inflammation and Autoimmunity, AstraZeneca, Mölndal, Sweden (R.J.L.); and Legacy R&D at Wilm
  • Artelsmair M; DMPK, IMED Oncology, AstraZeneca, Waltham, Massachusetts (C.G); Early Chemical Development, IMED Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (M.A., C.S.E); Medicinal Chemistry, IMED Respiratory Inflammation and Autoimmunity, AstraZeneca, Mölndal, Sweden (R.J.L.); and Legacy R&D at Wilm
  • Elmore CS; DMPK, IMED Oncology, AstraZeneca, Waltham, Massachusetts (C.G); Early Chemical Development, IMED Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (M.A., C.S.E); Medicinal Chemistry, IMED Respiratory Inflammation and Autoimmunity, AstraZeneca, Mölndal, Sweden (R.J.L.); and Legacy R&D at Wilm
  • Lewis RJ; DMPK, IMED Oncology, AstraZeneca, Waltham, Massachusetts (C.G); Early Chemical Development, IMED Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (M.A., C.S.E); Medicinal Chemistry, IMED Respiratory Inflammation and Autoimmunity, AstraZeneca, Mölndal, Sweden (R.J.L.); and Legacy R&D at Wilm
  • Davis P; DMPK, IMED Oncology, AstraZeneca, Waltham, Massachusetts (C.G); Early Chemical Development, IMED Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (M.A., C.S.E); Medicinal Chemistry, IMED Respiratory Inflammation and Autoimmunity, AstraZeneca, Mölndal, Sweden (R.J.L.); and Legacy R&D at Wilm
  • Hall JE; DMPK, IMED Oncology, AstraZeneca, Waltham, Massachusetts (C.G); Early Chemical Development, IMED Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (M.A., C.S.E); Medicinal Chemistry, IMED Respiratory Inflammation and Autoimmunity, AstraZeneca, Mölndal, Sweden (R.J.L.); and Legacy R&D at Wilm
  • Dembofsky BT; DMPK, IMED Oncology, AstraZeneca, Waltham, Massachusetts (C.G); Early Chemical Development, IMED Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (M.A., C.S.E); Medicinal Chemistry, IMED Respiratory Inflammation and Autoimmunity, AstraZeneca, Mölndal, Sweden (R.J.L.); and Legacy R&D at Wilm
  • Christoph G; DMPK, IMED Oncology, AstraZeneca, Waltham, Massachusetts (C.G); Early Chemical Development, IMED Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (M.A., C.S.E); Medicinal Chemistry, IMED Respiratory Inflammation and Autoimmunity, AstraZeneca, Mölndal, Sweden (R.J.L.); and Legacy R&D at Wilm
  • Smith MA; DMPK, IMED Oncology, AstraZeneca, Waltham, Massachusetts (C.G); Early Chemical Development, IMED Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (M.A., C.S.E); Medicinal Chemistry, IMED Respiratory Inflammation and Autoimmunity, AstraZeneca, Mölndal, Sweden (R.J.L.); and Legacy R&D at Wilm
  • Chapdelaine M; DMPK, IMED Oncology, AstraZeneca, Waltham, Massachusetts (C.G); Early Chemical Development, IMED Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (M.A., C.S.E); Medicinal Chemistry, IMED Respiratory Inflammation and Autoimmunity, AstraZeneca, Mölndal, Sweden (R.J.L.); and Legacy R&D at Wilm
  • Sunzel M; DMPK, IMED Oncology, AstraZeneca, Waltham, Massachusetts (C.G); Early Chemical Development, IMED Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (M.A., C.S.E); Medicinal Chemistry, IMED Respiratory Inflammation and Autoimmunity, AstraZeneca, Mölndal, Sweden (R.J.L.); and Legacy R&D at Wilm
Drug Metab Dispos ; 46(3): 303-315, 2018 03.
Article in En | MEDLINE | ID: mdl-29311137
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, GABA-A / Cyclization / Heterocyclic Compounds, 2-Ring Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Animals / Female / Humans / Male / Middle aged Language: En Journal: Drug Metab Dispos Journal subject: FARMACOLOGIA Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, GABA-A / Cyclization / Heterocyclic Compounds, 2-Ring Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Animals / Female / Humans / Male / Middle aged Language: En Journal: Drug Metab Dispos Journal subject: FARMACOLOGIA Year: 2018 Type: Article